The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity
Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Herrera A, Friedberg J, Friedman D, Schwartz C, Bergeron-Gravel S, Dama H, Roberts K, Constine L, Hodgson D. The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity. Blood 2021, 138: 881. DOI: 10.1182/blood-2021-147678.Peer-Reviewed Original ResearchInvolved site radiotherapyCardiac radiation doseInvolved-field radiotherapyChildhood Cancer Survivor StudyPositron emission tomographyMediastinal radiotherapyChildren's Oncology GroupDoxorubicin doseCumulative incidenceCardiac toxicityCardiac diseaseRT useCardiac riskCardiac disease riskBulk diseaseOncology GroupLymphoma trialsTrial protocolRadiation doseLong-term cardiac riskDisease riskCumulative doxorubicin doseImpact of nivolumabLate cardiac toxicityMean heart dosePrimary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria
Hoppe BS, Advani R, Milgrom SA, Bakst RL, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Mansur DB, Metzger ML, Pinnix CC, Plastaras JP, Roberts KB, Smith SM, Terezakis SA, Kirwan JM, Constine LS. Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 36-44. PMID: 33774076, DOI: 10.1016/j.ijrobp.2021.03.035.Peer-Reviewed Original ResearchConceptsPrimary mediastinal B-cell lymphomaMediastinal B-cell lymphomaB-cell lymphomaPET/CT responsePositron emission tomographyCell lymphomaDeauville scaleRadiation therapyCT responseAmerican Radium Society Appropriate Use CriteriaLong-term treatment-related morbiditySystematic reviewTreatment-related morbidityConsolidative radiation therapyAppropriate use criteriaEvidence-based guidelinesNon-Hodgkin lymphomaMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsChemoimmunotherapy strategiesCurable subtypeAdditional therapyChemoimmunotherapy regimensRefractory diseasePediatric oncologists